Yale Cancer Center

Kura Oncology Reports Positive Preliminary Ziftomenib Combination Data in Acute Myeloid Leukemia

Retrieved on: 
Tuesday, January 30, 2024
KURA, Failure, Acute myeloid leukemia, Venetoclax, Research, Division, MHS, Patient, Safety, QT interval, AML, Bone marrow, MBBS, QD, Yale Cancer Center, Disease, Therapy, Postcholecystectomy syndrome, Risk, ID, Cancer, Kura, Pharmaceutical industry

Continuous daily dosing of ziftomenib at 200 mg QD has been well tolerated and the safety profile consistent with features of underlying disease and backbone therapies.

Key Points: 
  • Continuous daily dosing of ziftomenib at 200 mg QD has been well tolerated and the safety profile consistent with features of underlying disease and backbone therapies.
  • The overall response rate (ORR) among R/R patients treated with ziftomenib and ven/aza was 53% (8/15).
  • As of the data cutoff, 80% (16/20) of patients remain on trial, including 100% (11/11) of all NPM1-m patients.
  • “We are highly encouraged by these preliminary combination data for ziftomenib and believe they support advancement into the frontline AML population,” said Troy Wilson, Ph.D., J.D., President and Chief Executive Officer of Kura Oncology.

GradSchoolCenter.com Releases Its Top Picks for the Graduate Research Centers That Are Making a Real Difference

Retrieved on: 
Wednesday, January 3, 2024
Disease, Yale University, UCLA, University, School, Student, Research, Brain, Vanderbilt University, MIT, Koch Institute, Cornell University, Johns Hopkins University, Harvard–Smithsonian Center for Astrophysics, AIMS, Alzheimer's disease, Ageing, Artificial intelligence, Stanford University, Columbia University, Arizona State University, Cancer, Duke University, Yale Cancer Center, Interdisciplinarity, Ohio State University, Texas A&M University, Coffee, Cornell Lab of Ornithology, Disorder, Harvard University, Nursing

NASHVILLE, Tenn., Jan. 3, 2024 /PRNewswire/ -- GradSchoolCenter.com has named the 20 graduate research centers that are integral to facilitating research and innovation efforts for academic and scientific advancement and to benefit the community at large.

Key Points: 
  • NASHVILLE, Tenn., Jan. 3, 2024 /PRNewswire/ -- GradSchoolCenter.com has named the 20 graduate research centers that are integral to facilitating research and innovation efforts for academic and scientific advancement and to benefit the community at large.
  • Numerous universities across America are a treasure trove for state-of-the-art research centers that significantly contribute to society.
  • Below is a link to our ranking report:
    We chose these schools based on the current and potential positive impact they make on society.
  • According to our lead researcher, Wendy Pigford, "The research centers are a hub for groundbreaking discoveries where engineers, scientists, and other accomplished experts in their fields collaborate with fellows and graduate students to cultivate an atmosphere of excellence."

Geron Announces IMerge Phase 3 Presentations at ASH Highlighting Significant Durability of Transfusion Independence and Breadth of Effect Across MDS Subgroups with Imetelstat in Lower Risk MDS

Retrieved on: 
Monday, December 11, 2023
Oncology, FDA, Health, Clinical Trials, Pharmaceutical, Biotechnology, Yale Cancer Center, Associate, International Prognostic Scoring System, Quality, IPSS, VAF, ASH, Acute myeloid leukemia, Cytopenia, Risk, Pros, Corporation, Yale school, Fatigue, Patient, Thrombocytopenia, Research, Periodic breathing, Imetelstat, Quality of life, Internal medicine, MDS, Neutropenia, MBBS, Yale School of Medicine, Bleeding, Survival, Pain, AML, Geron Corporation, Society, Iron overload, Mutation, RBC, Pharmaceutical industry, Dietary supplement, Lancet, Geron, SF3B1, Blood, Medicine, Hematology

The results showed that imetelstat consistently had higher RBC-TI response rates than placebo across these different risk subgroups.

Key Points: 
  • The results showed that imetelstat consistently had higher RBC-TI response rates than placebo across these different risk subgroups.
  • Overall, durable 24-week and 1-year RBC-TI responses were observed with imetelstat in all lower- and higher-risk subgroups.
  • This analysis suggests clinical benefit of imetelstat across different molecularly defined subgroups and independent of the underlying molecular mutation pattern.
  • This analysis indicates that achievement of RBC-TI was associated with improved survival, suggesting that transfusion dependence is a modifiable predictor of clinical outcomes in lower risk MDS.

Taiho Oncology Announces Presentation of Data From a U.S. Real-Word Study of Oral Decitabine and Cedazuridine

Retrieved on: 
Sunday, December 10, 2023
Yale Cancer Center, Bone marrow, Associate, Safety, Senior, Travel, ASH, MHS, Syndrome, HMA, Patient, Abstract, DEC, Medical Affairs Bureau, Index, Caregiver burden, MDS, MBBS, Yale School of Medicine, MHA, MD, Society, Majesty of the Seas, Pharmaceutical industry, Hematology

Data from the study were shared during an oral presentation ( Abstract #548 ) at the 65th American Society of Hematology (ASH) Annual Meeting & Exposition.

Key Points: 
  • Data from the study were shared during an oral presentation ( Abstract #548 ) at the 65th American Society of Hematology (ASH) Annual Meeting & Exposition.
  • Based on these results and the potential for reduced treatment burden, oral decitabine and cedazuridine may be a viable alternative to intravenous or subcutaneous HMAs."
  • In this study of 1,569 patients, 160 received oral DEC-C and 1,409 received intravenous/subcutaneous (IV/SC) HMAs.
  • As a leader in the development of orally administered anti-cancer agents, Taiho Oncology is pleased to see how outcomes of this real-world study show some of the potential benefits of an oral therapy in myelodysplastic syndromes."

EvolveImmune Therapeutics to Present New Preclinical and Translational Data Highlighting Precision Medicine Potential of its Novel Costimulatory T Cell Engager Platform at 38th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)

Retrieved on: 
Wednesday, October 18, 2023
EVOLVE, Regulation, Impact, Research, SITC, B7-H4, Immunotherapy, Yale Cancer Center, Tumor microenvironment, Immunology, Society, Cancer, Therapy, Patient, CD2, Neoplasm, Vaccine

BRANFORD, Conn., Oct. 18, 2023 (GLOBE NEWSWIRE) -- EvolveImmune Therapeutics, an immuno-oncology company developing first-in-category, multifunctional biotherapeutics to overcome the therapeutic challenges of cancer cell resistance to current immune therapy agents, today announced that new preclinical and translational data highlighting EVOLVE, the company’s novel costimulatory T cell engager platform, will be presented at the 38th Annual Meeting of the Society for Immunotherapy of Cancer (SITC), which is being held November 1-5, 2023, in San Diego, California. The poster presentations will unveil the company’s pioneering insights into the impact of tumor lineages on tumor antigen expression and immune infiltration in the tumor microenvironment. These features suggest the potential for patient-tailored immunotherapeutic strategies for EvolveImmune’s expanding pipeline of novel costimulatory T cell engagers.

Key Points: 
  • These features suggest the potential for patient-tailored immunotherapeutic strategies for EvolveImmune’s expanding pipeline of novel costimulatory T cell engagers.
  • The EVOLVE platform uniquely unleashes potent, selective and integrated T cell costimulation, which amplifies and sustains the tumor killing capacity of these T cells.
  • In two poster presentations, EvolveImmune will highlight how the differentiated aspects of the EVOLVE platform are being applied to two solid tumor programs, EV-104 and EV-106.
  • By supplying this second costimulatory signal to T cells, their cancer killing capacity is both heightened and prolonged.

Modifi Bio Raises Additional $4.3 Million in Seed Funding

Retrieved on: 
Monday, October 16, 2023
Cancer, DNA repair, Doctor of Philosophy, American Cancer Society, Kate, Yale Cancer Center, Investment, Ironwood, Yale school, DNA, Therapy, Oncology, Translation, Novo Nordisk, Halda Watch Company, Yale School of Medicine, Science, Drug discovery, National Brain Tumor Society, Pharmaceutical industry, European, HAVEN

NEW HAVEN, Conn., Oct. 16, 2023 (GLOBE NEWSWIRE) -- Modifi Biosciences, a leader in DNA modification as a novel approach to target cancer, today announced the closing of $4.3 million in a second round of seed financing, bringing the total raised to date to $10.7 million.

Key Points: 
  • NEW HAVEN, Conn., Oct. 16, 2023 (GLOBE NEWSWIRE) -- Modifi Biosciences, a leader in DNA modification as a novel approach to target cancer, today announced the closing of $4.3 million in a second round of seed financing, bringing the total raised to date to $10.7 million.
  • As part of the funding, Modifi Bio also announces the appointment of Kat Kayser-Bricker, PhD, Chief Scientific Officer of Halda Therapeutics, to the Board of Directors, who brings a wealth of expertise in drug discovery.
  • Additionally, Lucas de Breed, PhD MBA, will join as a board member, in his capacity as Director, Investments at BrightEdge.
  • At INKEF, he was instrumental in setting the investment strategy, building out the investment team and in expanding assets under management to $600 million.

First Cancer Moonshot Award Announced at Yale School of Medicine

Retrieved on: 
Tuesday, September 26, 2023
Emory University, Yale School of Medicine, Georgia Tech, DARPA, University, United States House Committee on Appropriations, Infection, Cancer, Yale Cancer Center, Yale school, Multimedia, Edelson, Lupus, RNA, Cell, Doctor of Philosophy, University of Georgia, ARPA, Messenger, Advanced Research Projects Agency for Health, Patient, Anthony, Immune system, Rosa DeLauro, Yale University, B cell, Virus, COVID19, Vaccine, Health, Dermatology, HAVEN, MD, Medicine

NEW HAVEN, Conn., Sept. 26, 2023 /PRNewswire/ -- Yale School of Medicine and Congresswoman Rosa DeLauro today announced the first Advanced Research Projects Agency for Health (ARPA-H) grant in the United States, which is an outgrowth of President Biden's Cancer Moonshot program.

Key Points: 
  • NEW HAVEN, Conn., Sept. 26, 2023 /PRNewswire/ -- Yale School of Medicine and Congresswoman Rosa DeLauro today announced the first Advanced Research Projects Agency for Health (ARPA-H) grant in the United States, which is an outgrowth of President Biden's Cancer Moonshot program.
  • The total award, distributed over three years, will be shared among collaborating teams at Emory University, Yale School of Medicine, and University of Georgia.
  • Richard Edelson , MD, the Anthony N. Brady Professor of Dermatology at Yale School of Medicine, and a former director of Yale Cancer Center, is a co-principal investigator on the project.
  • Edelson added that ARPA-H's crusade to encourage "moonshot" investigative team efforts in cancer is personal to all who have been affected by cancer.

Annals of Family Medicine: Researchers Describe Clinical Experiences of Transgender People, Recommend Strategies to Reduce Negative Health Consequences

Retrieved on: 
Monday, September 18, 2023
Medicalization, Annals of Family Medicine, Society, University, College, Physician, Curriculum, Empowerment, Yale Cancer Center, American Academy, North American Primary Care Research Group, Research, Multimedia, American Board of Family Medicine, American Board of Commissioners for Foreign Missions, Stigma, Family medicine, Patient, University of Rochester Medical Center, College of Family Physicians of Canada, American Academy of Family Physicians, Assault, Teacher, Safety, Nursing, Pharmaceutical industry, Annals

A new paper published in the September/October 2023 issue of Annals of Family Medicine describes the clinical experiences of transgender people.

Key Points: 
  • A new paper published in the September/October 2023 issue of Annals of Family Medicine describes the clinical experiences of transgender people.
  • Study authors also present short-term and long-term strategies towards reducing oppression and its health consequences among this patient population.
  • "Understanding the experiences of transgender people when their gender identities are known to clinicians and the reasons transgender people may share, modify, or withhold information could yield important clinical insights," the authors write.
  • Annals of Family Medicine is a peer-reviewed, indexed research journal that provides a cross-disciplinary forum for new, evidence-based information affecting the primary care disciplines.

A Phase 2 Study of Anti-Siglec-15 Antibody, NC318, in Combination with Pembrolizumab (NCT04699123) Demonstrates Clinical Activity in Patients with Advanced PD-1 Axis Inhibitor Refractory NSCLC

Retrieved on: 
Tuesday, September 12, 2023
Research Excellence Framework, Yale Cancer Center, Yale University, S15, Myelocyte, Yale School of Medicine, Special Program of Assisted Reproduction, Cancer research, Clinical trial, RECIST, Cancer, Trae tha Truth, SITC, Pneumonitis, DRS, Oncology, Research, Lung cancer, Rash, Psoriasis, HIV disease progression rates, Patient, Immunoglobulin G, Translational research, Pericarditis, Mab, Ensign, Transverse myelitis, PD-1, Pembrolizumab, United Technologies, Tumor microenvironment, Safety, Vaccine, Pharmaceutical industry, Medical imaging, Medicine, Dermatology, NSCLC, Pharmacology

BELTSVILLE, Md., Sept. 12, 2023 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced the presentation of Phase 2 clinical data by collaborators at the Yale Cancer Center demonstrating clinical benefit in patients with advanced, PD-1 axis inhibitor refractory non-small cell lung cancer (NSCLC) treated with a combination regimen of NC318, a Siglec-15 (S15) monoclonal antibody (mAb), and pembrolizumab, an anti-PD-1 antibody.

Key Points: 
  • In an earlier monotherapy study from NextCure, NC318 demonstrated single agent activity in a Phase 1/2 dose escalation trial (NCT03665285) for patients with advanced solid tumors (Tolcher et al, SITC 2019).
  • The ongoing NCT04699123 study is a randomized trial designed to assess the safety and efficacy of NC318 alone or in combination with pembrolizumab.
  • The combination portion of the study is assessing efficacy in NSCLC subjects who have experienced disease progression on, or after, PD-1 axis inhibitor therapy.
  • NC318 infusion reactions were seen in seven patients (three Grade 3, four Grade 2), six receiving the combination and one NC318 alone.

A.C. Camargo Cancer Center Harnesses the Power of DoseMe Precision Dosing Platform to Substantially Reduce Toxicity and Kidney Injuries

Retrieved on: 
Wednesday, August 30, 2023
Managed Care, Software, Research, Other Health, Pharmaceutical, Oncology, Technology, Infectious Diseases, Hospitals, Health Technology, Clinical Trials, Science, Health, BCPS, PM, Doctor of Pharmacy, University, Education, Evidence-based medicine, Post, Serum, Acute kidney injury, Survival, Infection, Cancer, International Association, Rehabilitation, Clinical endpoint, Doctor of Philosophy, ECCMID, Vancomycin, Patient, Collection, Nursing, Therapeutic drug monitoring, Diagnosis, Hospital, Yale Cancer Center, TDM, Pharmaceutical industry, Dosem

DoseMe , a leading provider of precision dosing software for therapeutic drug monitoring (TDM) and creators of DoseMeRx and DoseMe Analytics, today announced AC Camargo Cancer Center continues to recognize improved patient care with real world data dosing results.

Key Points: 
  • DoseMe , a leading provider of precision dosing software for therapeutic drug monitoring (TDM) and creators of DoseMeRx and DoseMe Analytics, today announced AC Camargo Cancer Center continues to recognize improved patient care with real world data dosing results.
  • A.C. Camargo is an integrated Cancer Center for diagnosis, treatment, education and research.
  • Since its inception in 1953, A.C. Camargo has made significant and ongoing contributions to the fight against cancer and it is recognized internationally as a reference institution.
  • "DoseMe is critical to our team's ability to access real-time data and continue to deliver on our promise of customized care for every single patient."